Goldline Pharmaceutical IPO, which opened for subscription on Tuesday, May 12, concluded its subscription today (May 14). The IPO of the Maharashtra-based pharmaceutical products marketing firm was subscribed 781.85 times on Thursday. The issue received bids for 1,53,86,88,000 shares against the 19,68,000 shares on offer.
Despite the strong subscription on the final day of bidding, the GMP for the SME IPO declined to Rs 15.
Investors will now look forward to the Goldline Pharmaceutical IPO share allotment status on Friday, May 15. The shares are set to debut on the BSE SME platform, with the tentative listing date scheduled for May 19.
Here's a look at the Goldline Pharmaceutical IPO details including the detailed final subscription status, the latest GMP, and other important details.
Goldline Pharmaceutical IPO Day 3 Subscription Status
Retail investors drove the demand, subscribing to their portion 881.15 times. The Non-Institutional Investor (NII) category was booked 1227.90 times, while the Qualified Institutional Buyers (QIB) segment saw a subscription of 180.22 times.
Goldline Pharmaceutical IPO Latest GMP
According to InvestorGain, Goldline Pharmaceutical SME IPO's latest GMP stands at Rs 15 on May 14. Based on the upper end of the price band of Rs 43, the estimated listing price stands at Rs 58 per share, implying a potential gain of 34.88% on listing.
The grey market premium for Goldline Pharmaceutical IPO was as high as Rs 25 when the issue opened for Day 3 subscription, indicating a possible listing gain of more than 55%.
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO is a book-built issue of Rs 11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh shares. The price band was fixed between Rs 41 and Rs 43 per share. The minimum lot size for retail investors is 3,000 shares. Retail investors must apply for at least two lots, or 6,000 shares, taking the minimum investment amount to Rs 2.58 lakh. For HNI investors, the minimum application size is three lots, or 9,000 shares, amounting to Rs 3.87 lakh.
Cumulative Capital Pvt. Ltd. is the book-running lead manager for the issue, while Bigshare Services Pvt. Ltd. is the registrar. Nirman Share Brokers Pvt. Ltd. is the market maker for the IPO.
About Goldline Pharmaceutical
Goldline Pharmaceutical operates across multiple therapeutic segments. The company's portfolio is divided into five segments. Goldline Pharma has 42 products focused on specialities such as orthopaedics, ENT, gastroenterology, neurology, urology and surgery.
Goldline Cardinal offers 54 products for physicians, diabetologists, endocrinologists and cardiologists. Goldline Aayushman includes 18 products catering to paediatricians, neonatologists and child specialists. Goldline InLife has 22 products aimed at intensivists, critical care consultants and super-speciality surgeons. Goldline Wellness includes 10 products focused on supportive care in cancer treatment.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
